Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1981 1
1982 3
1983 6
1984 8
1985 9
1986 4
1987 9
1988 5
1989 11
1990 8
1991 3
1992 7
1993 5
1994 5
1995 3
1996 5
1997 7
1998 6
1999 6
2000 4
2001 7
2002 6
2003 9
2004 6
2005 3
2006 6
2007 8
2008 11
2009 10
2010 4
2011 6
2012 6
2013 2
2014 13
2015 4
2016 11
2017 13
2018 9
2019 10
2020 12
2021 9
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Vilaseca A, Farina A, Villagrán-García M, Pegat A, Benaiteau M, Ciano-Petersen NL, Do LD, Rogemond V, Gonçalves D, Psimaras D, Birzu C, Honnorat J, Joubert B. Vilaseca A, et al. J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252-0. Online ahead of print. J Neurol. 2024. PMID: 38467790
BACKGROUND: The clinical spectrum of melanoma-associated neurological autoimmunity, whether melanoma-associated paraneoplastic neurological syndromes (PNS) or induced by immune checkpoint inhibitors (ICI), is not well characterized. We aim to describe …
BACKGROUND: The clinical spectrum of melanoma-associated neurological autoimmunity, whether melanoma-associated …
Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.
Hashimoto K, Nishimura S, Shinyashiki Y, Ito T, Kakinoki R, Akagi M. Hashimoto K, et al. Medicine (Baltimore). 2023 Jun 2;102(22):e33908. doi: 10.1097/MD.0000000000033908. Medicine (Baltimore). 2023. PMID: 37266606 Free PMC article.
The involvement of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma-associated antigen A4 (MAGE-A4) in soft-tissue sarcoma pathogenesis has recently been reported; however, their involvement in desmoid tumors (DTs) remains unknown. ...The …
The involvement of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma-associated antigen A4 (MAGE-A4 …
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR Jr, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Hong DS, et al. Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9. Nat Med. 2023. PMID: 36624315 Free PMC article. Clinical Trial.
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/ …
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leuk …
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD, Petroni GR, Mauldin IS, Chianese-Bullock KA, Olson WC, Smith KT, Dengel LT, Haden K, Grosh WW, Kaur V, Varhegyi N, Gaughan EM, Slingluff CL Jr. Vavolizza RD, et al. J Immunother Cancer. 2022 Sep;10(9):e005424. doi: 10.1136/jitc-2022-005424. J Immunother Cancer. 2022. PMID: 36100309 Free PMC article. Clinical Trial.
BACKGROUND: A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active. ...
BACKGROUND: A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and c …
Granular variant of a histiocytic tumor on the toe of a cat: Case report and literature review.
Cruz Otero JD, Jager M, Armien AG, Miller A, Stokol T. Cruz Otero JD, et al. Vet Clin Pathol. 2023 Mar;52(1):102-107. doi: 10.1111/vcp.13152. Epub 2022 Jun 24. Vet Clin Pathol. 2023. PMID: 35751153 Review.
The tumor cells did not express CD3, CD20, CD117, pancytokeratin (AE1/AE3), melanoma antigen (Melan-A), multiple myeloma oncogene-1 (MUM1), melanoma-associated antigen (PNL-2), and S-100. Low numbers of tumor cells expressed CD204 and protein gene prod …
The tumor cells did not express CD3, CD20, CD117, pancytokeratin (AE1/AE3), melanoma antigen (Melan-A), multiple myeloma oncogene-1 ( …
Blockade of TIM-3 and PD-1 enhances the antitumor effects of MAGE-A11 antigen-specific cytotoxic T lymphocytes.
Zhang J, Zhang F, Wu H, Zhang B, Zhang X, Wu X. Zhang J, et al. Bull Cancer. 2022 Sep;109(9):895-908. doi: 10.1016/j.bulcan.2022.04.005. Epub 2022 Jun 14. Bull Cancer. 2022. PMID: 35710477
Cancer immunotherapy is an attractive approach for antigen-specific T cell-mediated antitumor therapy, especially for the induction of cytotoxic T lymphocytes (CTLs). An human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen-A11 …
Cancer immunotherapy is an attractive approach for antigen-specific T cell-mediated antitumor therapy, especially for the induction o …
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Hong DS, et al. Front Oncol. 2022 Mar 18;12:818679. doi: 10.3389/fonc.2022.818679. eCollection 2022. Front Oncol. 2022. PMID: 35372008 Free PMC article.
BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity melanoma-associated antigen (MAGE)-A10-specific T-cell receptor (TCR) targeting MAGE-A10-positive tumo …
BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express …
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger de Spéville B, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Blumenschein GR, et al. J Immunother Cancer. 2022 Jan;10(1):e003581. doi: 10.1136/jitc-2021-003581. J Immunother Cancer. 2022. PMID: 35086946 Free PMC article. Clinical Trial.
BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting MAGE-A …
BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells …
Proteomic Signatures of Diffuse and Intestinal Subtypes of Gastric Cancer.
Singh S, Bhat MY, Sathe G, Gopal C, Sharma J, Madugundu AK, Joshi NS, Pandey A. Singh S, et al. Cancers (Basel). 2021 Nov 25;13(23):5930. doi: 10.3390/cancers13235930. Cancers (Basel). 2021. PMID: 34885041 Free PMC article.
This quantitative mass spectrometric analysis defined a proteomic signature of differential expression across the two subtypes, which included gremlin1 (GREM1), bcl-2-associated athanogene 2 (BAG2), olfactomedin 4 (OLFM4), thyroid hormone receptor interacting protein 6 (TRIP6) an …
This quantitative mass spectrometric analysis defined a proteomic signature of differential expression across the two subtypes, which includ …
MAGEH1 interacts with GADD45G and induces renal tubular cell apoptosis.
Shin GT, Park JE, Lee MJ. Shin GT, et al. PLoS One. 2021 Nov 17;16(11):e0260135. doi: 10.1371/journal.pone.0260135. eCollection 2021. PLoS One. 2021. PMID: 34788311 Free PMC article.
BACKGROUND: Melanoma-associated antigen H1 (MAGEH1) is a protein that belongs to melanoma-associated antigen (MAGE) superfamily. ...Accordingly, CsA-induced apoptosis was significantly decreased in MAGEH1 siRNA and GADD45G siRNA transfect …
BACKGROUND: Melanoma-associated antigen H1 (MAGEH1) is a protein that belongs to melanoma-associated a …
274 results